My Community - Clinical Information


The following are published, peer-reviewed papers on the latest research and clinical studies related to Cerezyme® and Gaucher disease. Reading the abstracts of these papers will help keep you informed and up-to-date on news and advances in this medical field.

Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease.
Maas M, Hangartner T, Mariani G, Skeletal Radiol. 2008 Mar;37(3):185-8.
Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
Drelichman G, Ponce E, Basack N, et al. J Pediatr. 2007 Aug;151(2):197-201.
Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ, Kacena KA, Kaplan P, et al. J Bone Miner Res. 2007;22:119-126.
Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.
Weinreb N, Barranger J, Packman S, et al. Clin Genet. 2007;71:576-588.
The long-term international safety experience of imiglucerase therapy for Gaucher disease
Starzyk K, Richards S, Yee J, et al. Mol Genet Metab. 2007;90:157-163.
The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.
Kaplan P, Andersson HC, Kacena KA, et al. Arch Pediatr Adolesc Med. 2006;160:603-608.
Individualization of long-term enzyme replacement therapy for Gaucher disease.
Andersson HC, Charrow J, Kaplan P, et al. Genet Med. 2005 Feb;7(2):105-10.
Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease:
consensus recommendations. Charrow J, Andersson HC, Kaplan P, et al. J Pediatr. 2004 Jan;144(1):112-20. Review.
The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J, Dulisse B, Grabowski GA, et al. Clin Genet. 2007;71:205-211.
Therapeutic goals in the treatment of Gaucher disease.
Pastores GM, Weinreb NJ, Aerts H, et al. Semin Hematol. 2004;41(Suppl 5):4-14.
The International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients.
Weinreb NJ, Aggio MC, Andersson HC, et al. Semin Hematol. 2004;41(Suppl 5):15-22.

Read more clinical information about Gaucher disease in Sanofi Genzyme Gaucher Research